Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Scancell provides update on its drug discovery pipeline

Oct. 3, 2013

Phase I/II trial of Mologen's renal cancer vaccine meets primary endpoints

Oct. 2, 2013

FDA grants accelerated approval of new indication for Perjeta

Oct. 2, 2013

MEDI-4736 treatment results in significant tumor suppression

Oct. 2, 2013

New French biotechnology company formed to develop MAb for ovarian cancer

Oct. 2, 2013

Results of phase III trial demonstrate improvements in PFS and PSA responses with ipilimumab

Oct. 1, 2013

Etubics receives SBIR grant for breast cancer immunotherapeutic

Oct. 1, 2013

Phase I results show promising oncolytic activity for the anti-HB-EGF antibody U3-1565

Sep. 30, 2013

Eli Lilly reports topline results from two global phase III ramucirumab studies

Sep. 30, 2013

Mologen submits MGN-1703 IND application with FDA

Sep. 27, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...